A Beam Therapeutics gene-editing therapy designed to fix a mutation at the root of a rare liver protein deficiency now has ...
The one-time therapy appears to correct the mutation that causes the disease, known as Alpha-1 antitrypsin deficiency (AATD), ...
While initial study results suggest Beam's technology can correct alpha-1 antitrypsin deficiency's genetic roots, shares fell ...
Early research shows a one-time gene therapy has potential for addressing both the liver and lung disease that patients with ...
The small study in patients with a rare disorder that causes liver and lung damage showed the potential for precisely ...
BEAM-302 "has set the bar for efficacy in this space," William Blair analysts wrote in an investor note on Monday.
Armed with new proof-of-concept data showing that its in vivo base-editing therapy BEAM-302 can correct the gene mutation in ...
The Cambridge-based company touted the data as evidence of the first successful use of CRISPR gene editing to fix a ...
Proton Beam Therapy is highly effective for treating tumours in sensitive areas, since by reducing exposure of healthy ...